ABSTRACT
PURPOSE: With improved diagnostic techniques and treatments of breast cancer, overall survival times are longer, giving more opportunity for normal tissue complications of treatment to manifest. Radiation late effects (RLEs) could have profound long-term impacts on the quality of life of the survivors. The aim of this study was to identify predictive factors influencing timing and types of complications in patients referred to the Adult Radiation Late Effects Clinic (ARLEC). METHODS: In a period of 16 years, 296 breast cancer patients were referred to the ARLEC. The clinical records were retrospectively studied to collect epidemiologic, medical and treatment data. Associations were sought between candidate predictive factors and time to the first complication after radiation treatment (RT) completion (primary outcome), and pain or swelling (secondary outcomes) using univariable and multivariable linear and logistic regression analyses. All analyses were performed in SAS, version 9.4. RESULTS: All patients were female with a mean age of 56.3 years. The first treatment-related complication occurred after a median of 3 months. Patients were followed at ARLEC for a median of 18 months. Older age and delay from surgery to RT (S-RT delay) were associated with earlier onset of complications (both p < 0.001). The most common complications were breast pain (62.1%) and swelling (45.9%). Histology and RT boost were associated with pain (p = 0.035 and 0.013). RT boost and S-RT delay on the other hand were associated with swelling (p = 0.013 and 0.005). CONCLUSIONS: Clinical factors identified could help recognize the patients at high risk for developing RLEs and alert physicians to initiate earlier diagnostic and therapeutic measures.
Subject(s)
Breast Neoplasms/radiotherapy , Cancer Survivors , Radiation Injuries/epidemiology , Aged , Breast Neoplasms/pathology , Female , Humans , Middle Aged , Radiation Injuries/etiology , Radiation Injuries/therapy , Retrospective Studies , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
Se presentan 9 casos de melanoma tratados con Tamoxifen, solo o asociado a DTIC. En cuatro de ellos el tratamiento postquirurgico fue precaucional. Otros 4 presentaron metastasis; 2 de ellos murieron poco despues de iniciado el tratamiento; los otros 2 se hallan en remision estando en tratamiento desde hace 1 y 3 anos. En un paciente no operado, el tratamiento comenzo hace 2 anos, hallando-se actualmente en estado estacionario favorable. El tamoxifen se administro en forma permanente en dosis de 30 mg diarios. No se observaron reacciones adversas.dosis de 30 mg diarios. No se observaron dosis de 30 mg diarios. No se observaron dosis de 30 mg diarios. No se observaron reacciones adversas
Subject(s)
Adult , Middle Aged , Humans , Male , Female , Melanoma , TamoxifenABSTRACT
Se presentan 9 casos de melanoma tratados con Tamoxifen, solo o asociado a DTIC. En cuatro de ellos el tratamiento postquirurgico fue precaucional. Otros 4 presentaron metastasis; 2 de ellos murieron poco despues de iniciado el tratamiento; los otros 2 se hallan en remision estando en tratamiento desde hace 1 y 3 anos. En un paciente no operado, el tratamiento comenzo hace 2 anos, hallando-se actualmente en estado estacionario favorable. El tamoxifen se administro en forma permanente en dosis de 30 mg diarios. No se observaron reacciones adversas.dosis de 30 mg diarios. No se observaron dosis de 30 mg diarios. No se observaron dosis de 30 mg diarios. No se observaron reacciones adversas